1. Home
  2. PRLD vs AP Comparison

PRLD vs AP Comparison

Compare PRLD & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • AP
  • Stock Information
  • Founded
  • PRLD 2016
  • AP 1929
  • Country
  • PRLD United States
  • AP United States
  • Employees
  • PRLD N/A
  • AP N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • AP Fluid Controls
  • Sector
  • PRLD Health Care
  • AP Industrials
  • Exchange
  • PRLD Nasdaq
  • AP Nasdaq
  • Market Cap
  • PRLD 48.6M
  • AP 54.7M
  • IPO Year
  • PRLD 2020
  • AP N/A
  • Fundamental
  • Price
  • PRLD $0.78
  • AP $2.90
  • Analyst Decision
  • PRLD Strong Buy
  • AP
  • Analyst Count
  • PRLD 2
  • AP 0
  • Target Price
  • PRLD $4.50
  • AP N/A
  • AVG Volume (30 Days)
  • PRLD 221.0K
  • AP 67.0K
  • Earning Date
  • PRLD 08-11-2025
  • AP 08-11-2025
  • Dividend Yield
  • PRLD N/A
  • AP N/A
  • EPS Growth
  • PRLD N/A
  • AP N/A
  • EPS
  • PRLD N/A
  • AP 0.22
  • Revenue
  • PRLD $7,000,000.00
  • AP $412,355,000.00
  • Revenue This Year
  • PRLD N/A
  • AP N/A
  • Revenue Next Year
  • PRLD N/A
  • AP N/A
  • P/E Ratio
  • PRLD N/A
  • AP $13.46
  • Revenue Growth
  • PRLD N/A
  • AP N/A
  • 52 Week Low
  • PRLD $0.61
  • AP $0.74
  • 52 Week High
  • PRLD $6.80
  • AP $3.99
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 42.16
  • AP 47.41
  • Support Level
  • PRLD $0.77
  • AP $2.80
  • Resistance Level
  • PRLD $0.84
  • AP $3.08
  • Average True Range (ATR)
  • PRLD 0.07
  • AP 0.17
  • MACD
  • PRLD -0.02
  • AP -0.05
  • Stochastic Oscillator
  • PRLD 16.04
  • AP 20.83

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About AP Ampco-Pittsburgh Corporation

Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.

Share on Social Networks: